Explore the complete list of our presses below (Page 24 of 27):
Biomea Fusion activates an icovamenib plus semaglutide arm in Leicester's OPAL platform trial. Enrollment opens Q3 2026; Week 24 primary outcomes cover muscle, bone, and metabolic endpoints.
Omnix Medical doses first Phase II patients with OMN6 for drug-resistant Acinetobacter baumannii. Key GMP, CMC, and process validation implications for sterile manufacturers.
FDA publishes real-world evidence landscape analysis covering approvals, labeling changes, and no-action determinations across CDER, CBER, and CDRH since 2011.
Novartis files secukinumab for polymyalgia rheumatica in three major markets after Phase III REPLENISH data showed double the sustained remission rate vs placebo.
Celularity names Rick Gonzalez Chief Commercial Officer to lead cenplacel-L and Lifebank commercialization across permissive international markets. Effective May 29, 2026.
Becton Dickinson issues Class I correction for BD Spinal Trays after GMP failures at bupivacaine supplier Huons Co., Ltd. QA and supply chain implications examined.
FDA's state collaboration framework on compounding oversight is evolving. Key updates on DQSA Section 105, MOU rulemaking, and inspection data sharing for 503A and 503B facilities.
DST-backed Pune researchers develop targeted gene-silencing nanomedicine for breast cancer. Key GMP and CDMO implications for oncology formulators and QA leads.
CII appoints Manni Kantipudi and Manoj Kumar R. Panicker to lead its CRDMO task force, targeting policy advocacy and global competitiveness for Indian contract manufacturers.
Novartis's 2.5-year ALIGN Phase III results show Vanrafia slows eGFR decline in IgAN, supporting a 2026 traditional approval submission after 2025 accelerated approvals.
Dr. Rajesh Jain chairs CII's National Biotechnology Committee. Implications for India's biosimilar manufacturing policy, vaccine development frameworks, and CDSCO regulatory alignment.
Ipca Laboratories names Dr. Sandarbh Rishi Head of MSAT and Pilot Plant. He brings 15+ years in bioprocess development, fermentation, and technology transfer.
Bioneemtec India receives Technology Development Board support to commercialize indigenous green chemistry technologies for critical pharmaceutical ingredient manufacture.
Plus Therapeutics' CNSide Diagnostics secures CAP Laboratory Accreditation for its Houston lab, supporting payer access and health-system adoption of its CNS cancer CSF assay.
BeyondSpring restructures leadership around its DUBLIN-4 confirmatory Phase 3 program for Plinabulin in NSCLC. New CEO Min Qiu and CFO Na Li take effect July 1, 2026.
LeonaBio targets H2 2026 for an adaptive Phase 2 ALS trial of brelgometon, integrating neurofilament light chain biomarkers following successful Phase 1 data.
Celularity deploys cenplacel-L under Florida's new state investigational use law. Key GMP, compliance, and regulatory implications for cell therapy manufacturers.
Gelteq establishes a Guangdong Center of Excellence to accelerate formulation development and access China's US$60B cross-border biopharma licensing market.
Oncovita reports complete remission data for MVdeltaC across four solid tumour models. GMP manufacturing via CDMO targets clinical trials by end of 2027.
Teva launches AHZANTIVE aflibercept biosimilar in four European markets following EC approval. Key implications for QA, supply chain, and biosimilar commercialization strategy.
Novo Nordisk debuts oral Wegovy in the UAE, the first market outside the US. QA and regulatory leads face CMC, cold-chain, and dossier sequencing implications.
ResMed's $340M acquisition of Noctrix Health expands its sleep therapy portfolio and triggers QMS integration, 21 CFR Part 820 change control, and regulatory review.
Alembic Pharmaceuticals names Ramesh Juneja EVP Human Health for India. Implications for GMP compliance, process validation, and formulations pipeline management.
Steps Biosciences and RDGVRP open a Bengaluru formulations R&D centre for sterile injectables and complex drug delivery. Key implications for QA and regulatory leads.
FDA licenses ModernaTX's MNEXSPIKE COVID-19 mRNA vaccine under STN 125835. Key regulatory documents and a layered approval timeline reviewed for biologics manufacturers.
Glenmark enters the US with generic Lacosamide Injection USP, targeting a $15.2M hospital-use market. Key read for QA directors and regulatory affairs leads.
Suven Life's Masupirdine Phase 3 Alzheimer's trial clears DSMB interim review without modifications at 88% enrollment. Key implications for CMC and scale-up planning.
CBC India's exclusive deal with Metalco-Alupack expands access to seamless anodized aluminium packaging for sterile APIs, with GMP and regulatory implications for Indian pharma.
Aurobindo Pharma launches TheraNym, India's largest biologics CMO, with MSD as anchor customer. Key implications for biologics outsourcing and CDMO qualification.
Teva's real-world AUSTEDO and AUSTEDO XR survey shows 74% of HD chorea patients reporting movement improvement and reduced caregiver burden post-treatment.
Independent survey scores Annamycin 6/7 on physician prescribe intent in R/R AML. Payers signal support. CMC and NDA planning implications examined.
Finerenone shows efficacy beyond diabetic CKD. Pharma Now examines sNDA filing strategy, 21 CFR Part 314 obligations, and manufacturing scale-up implications.
Intas Pharmaceuticals names Muthukumar Anbalagan General Manager for NDDS, reinforcing its complex formulations push into US and EU regulated markets.
Teva launches AHZANTIVE biosimilar across Europe for ophthalmic disease. Key implications for GMP fill-finish, EMA regulatory pathways, and biosimilar competition.
FDA and M-CERSI host a July 2026 workshop on pediatric SLE extrapolation strategies. Key implications for sponsors developing biologics in autoimmune indications.
FDA confirms Burkholderia cepacia in Target Up & Up baby wipes. Recall covers 8 SKUs from supplier Sapro Temizlik Urunleri. Key read for QA and manufacturing leads.
Zealand Pharma's ZUPREME-1 Phase 2 trial shows petrelintide achieving up to 10.7% weight loss with low GI discontinuation. Phase 3 trials planned H2 2026.
FDA requires SAX-HPLC, NMR spectra, and Certificates of Analysis for all heparin imports. QA and regulatory teams must meet USP standards or risk delayed entry.
FDA urges manufacturers to reintroduce bovine heparin to diversify porcine supply chains, outlining pre-IND and CMC requirements under 21 CFR 312.23(a)(7)(i).
Sanofi deploys a Snowflake Cortex AI conversational agent for sales reps. QA and regulatory leads should note the data governance and audit trail implications.
Africa CDC and WHO launch a $518M Bundibugyo Ebola response plan with no licensed species-specific vaccines or therapeutics — key implications for CDMO and biotech pipelines.
Survodutide Phase III trials confirm 34% visceral fat and 63% liver fat reduction. What CDMOs and fill-finish operations need to anticipate as regulatory submission nears.
Survodutide met Phase III endpoints in obesity and MASLD trials, showing 34% visceral and 63% liver fat reductions. Key regulatory and CMC implications examined.
LENZ Therapeutics transfers VIZZ Greater China rights to Everest Medicines. NMPA NDA filed Sept 2025, Q1 2027 approval targeted. Up to $85M in milestones retained.
Lupin Manufacturing Solutions names Eduardo Jule Chief Commercial Officer to drive CDMO and API growth in US and EU regulated markets.
Everest Medicines secures exclusive Asia-Pacific licensing rights for Bejescin. Regulatory and manufacturing implications across NMPA, PMDA, and TGA jurisdictions.
Nurix and Roche sign a $2.3B deal for BTK degrader bexobrutideg. What plant heads and QA directors need to know about degrader manufacturing and GMP implications.
Roche and Nurix sign a global co-development deal for BTK degrader bexobrutideg. Phase 3 CLL launch in 2026 raises key GMP and process validation questions.
Intravacc expands integrated analytical services for vaccine and biologics developers, covering CMC package development, IMPD documentation, and GMP campaign readiness.
Cormica names Caroline Aiken Technical Director to align analytical, regulatory, and testing capabilities across its global CRO laboratory network from June 2026.
Novartis presents remibrutinib Phase III and extension data across urticaria and food allergy at EAACI 2026, with CMC and regulatory implications for QA teams.
Intravacc formalises integrated analytical development services to reduce CMC risk and accelerate IND readiness for vaccine and biologics developers.
Sanofi's Sarclisa SC becomes the EU's first anticancer therapy approved via on-body injector. Key OBI manufacturing and EMA regulatory implications for QA directors.
Maiva Pharma commissions a sterile injectables facility in Tamil Nadu for generic and complex products. Key GMP and supply chain implications for regulated markets.
Eledon's tegoprubart delivered insulin independence in all 12 islet transplant patients with no rejection episodes, reshaping GMP and immunosuppression protocol considerations.
Tonix Pharmaceuticals secures a second GPO agreement for TONMYA cyclobenzaprine HCl sublingual tablets, reaching 52 million U.S. commercial lives within 30 days of launch.
Medicus Pharma submits EU CTIS substantial modification to advance Teverelix Phase 2b in high cardiovascular-risk prostate cancer. Registrational development targeted for 2026.
Teva's three-study AUSTEDO data package from Psych Congress Elevate 2026 extends real-world evidence for deutetrabenazine in mild and long-term tardive dyskinesia management.
FDA's updated Generic Drugs Q&A covers nitrosamine controls, bioequivalence standards, inspection outcomes, and MedWatch obligations. Key compliance reference for QA teams.
Haleon commits Rs. 2,000 crore to a greenfield manufacturing facility in Madhya Pradesh, its first in India, with implications for GMP standards and supply chain.
Novo Nordisk's zenagamtide posts 14.6% weight loss in phase II. What the dual GLP-1/amylin data mean for fill-finish capacity and process validation planning.
Roche's $2.3B bexobrutideg licensing deal with Nurix raises GMP and process validation challenges for CMOs handling PROTAC-class degraders.
Optimi Health begins ibogaine finished drug product development at its Health Canada-licensed GMP facility in BC, targeting clinical trial supply under accelerated FDA review.
Abbott's Healthy Food Rx study shows medication adherence rose from 57% to 94% in 284 diabetes patients when food boxes were paired with community health worker coaching.
Medera appoints three cardiopulmonary experts to its SAB as SRD-002, its intracoronary AAV HFpEF gene therapy, advances toward its next clinical milestone.
FDA revised inhalation product guidances on May 21, 2026 and approved the first GLP-1 generic. Key implications for ANDA strategy, CGMP compliance, and inspection readiness.
FDA's December 2024 approval of Grifols' VISTASEAL Fibrin Sealant under BL 125640 documents a multi-supplement BLA lifecycle relevant to biologics regulatory strategy.
FDA publishes BsUFA II final assessment covering biosimilar 351(k) BLA review transparency and communication program. Key implications for regulatory teams.
Merck KGaA names Clara Sattler de Sousa e Brito to lead Discovery Solutions from Q3 2026 and Robert Machinek as Head of Strategy, with implications for CMO sourcing.
Pfizer's VESPER mid-stage data for berobenatide show strong weight loss results, raising fill-finish, peptide stability, and cold-chain challenges ahead of Phase III.
SPI Pharma completes acquisition of Elementis Pharma, adding German GMP manufacturing and specialty excipients. Key implications for QA and procurement teams.
Lupin partners with Laboratorios ERN to launch Luforbec inhaler in Spain, combining EU GMP manufacturing capability with local commercial infrastructure.
Eli Lilly's ATTAIN Phase 3 data show oral GLP-1 fat loss across menopause stages. What it means for formulation science, process validation, and GMP scale-up.
AstraZeneca's Ultomiris hit a 43.4% UPCR reduction in Phase III IgA nephropathy trial. What it means for FDA/EMA filing and biologics manufacturing.
Idorsia refinances its May 2027 debt with a CHF 250M senior secured loan from Pharmakon Advisors, extending cash runway into 2028 and stabilising commercial operations.
Aurobindo Pharma USA names Punita Kumar-Sinha as Independent Director. See what her investment background means for manufacturing investment and FDA compliance priorities.
Merck formalises an MoU with CSIR-IICT for joint research and knowledge exchange, deepening multinational pharma engagement with India's public research sector.
Lilly targets Q2 2026 FDA submission for oral GLP-1 orforglipron after phase 3 superiority over semaglutide. Key implications for solid dosage manufacturing and CMOs.
Alembic Therapeutics acquires NUVESSA (metronidazole vaginal gel 1.3%) from Exeltis USA, shifting GMP, NDA, and distribution obligations to the new owner.
FDA clears Imviva Biotech's IND for CTA313, an allogeneic CD19/BCMA CAR-T therapy. Key manufacturing and batch-release implications for cell therapy CMOs and QA directors.
FDA finalizes bemotrizinol as the first new OTC sunscreen active ingredient in 20+ years under the CARES Act administrative order process. Key facts for OTC manufacturers.
FDA warns Zydus Lifesciences over 21 CFR 211.84 failures at Baddi. IR testing gaps missed carcinogen contamination risk across multiple drug product lots.
FDA posts untitled letters against manufacturers in India, China, Italy, and the U.S. QA and regulatory teams should audit supplier lists against CDER FOIA records.
Lilly's triple agonist retatrutide posts late-stage obesity results. What plant heads and CDMOs need to know about API complexity and fill-finish capacity.
Bristol Myers Squibb activates a multiple myeloma awareness campaign with Mariska Hargitay. Key compliance and regulatory implications for pharma affairs teams.
Yashoda Medicity receives DGME approval for a brain stem death certification committee, fulfilling a key THOTA requirement for deceased donor organ procurement in India.
Medtronic gains CE Mark for Stealth AXiS surgical navigation system in Europe. Key reference for regulatory teams tracking EU MDR 2017/745 conformity timelines.
FDA revoked Moderna's COVID-19 EUA on Aug 27, 2025. QA and regulatory teams must align Spikevax operations with full BLA, GMP, and post-market requirements.
FDA CDER closes dual warning letters against Delta Kozmetik after five years. What the closure language means for foreign manufacturers and QA compliance teams.
AB Science's masitinib achieves 42.3% five-year ALS survival in Phase 2b/3 trial AB10015, doubling historical benchmarks. ENCALS 2026 presentation set for 25 June.
FDA grants RMAT designation to Cellectis's lasme-cel allogeneic CAR-T for r/r B-ALL. What it means for CDMOs and cell therapy manufacturers building off-the-shelf capabilities.
Medexus secures exclusive Canadian rights to Zemcelpro® (dorocubicel) in a deal with ExCellThera. Commercialization targeted for 2028–2031 pending Health Canada approval.
FDA's Compounding Quality Center of Excellence launches two discussion series and a cross-sector group for outsourcing facilities to benchmark cGMP and address drug shortages.
GSK's $10.6B Nuvalent acquisition adds ROS1/ALK inhibitors zidesamtinib and neladalkib, triggering CMC integration and GMP planning obligations for QA and regulatory teams.
AmMax Bio licenses Lonza's SYNtecan ADC platform for AML candidate AMB-104, targeting a 2027 IND filing. Key implications for CMC leads and CDMO capacity planning.
Sanofi stops MOBILIZE phase 3 riliprubart study in refractory CIDP after DMC futility finding. VITALIZE continuation under review. No safety signals identified.
Tilray Medical Germany launches ARX cannabis brand from its EU-GMP Aphria RX facility in Neumünster, with Broken Coast genetics and national pharmacy distribution.
Axplora transfers all UDCA API production to its FDA-approved Vizag site by end of 2026, centralising supply and refocusing Farmabios on HPAPI manufacturing.
FDA revises alli orlistat Drug Facts Label for kidney injury and nephrolithiasis risk, harmonizing safety language across OTC and Rx orlistat products. Compliance implications for manufacturers.
ALK-Abello's ODACTRA has seven CBER approval actions from 2017–2025. A key case study for allergen extract manufacturers managing iterative BLA supplement cycles.
FDA revoked the Pfizer-BioNTech COVID-19 EUA on August 27, 2025. QA and regulatory leads must address labeling changeovers, lot release, and GMP compliance under full BLA approval.
FDA's 2026 Drug Safety Communications require labeling changes for orlistat, carbidopa/levodopa, GLP-1 RAs, and opioids. QA and regulatory teams must act now.
Optimi Health completes first GMP psilocybin export to the UK under dual Health Canada and Home Office authorization, setting a supply template for psychedelic clinical programs.
FDA and NIH host three-part virtual training on ClinicalTrials.gov registration and results reporting for sponsor-investigators. Sessions run July 14, 22, and 30, 2026.
Axplora exits Italian UDCA production and consolidates global API supply at Vizag. Key implications for site-change filings, supply risk, and ICH Q7 compliance.
Teva closes $700M Emalex acquisition, targeting H2 2026 NDA submission for ecopipam in pediatric Tourette syndrome. FDA Fast Track and Orphan Drug designations in place.
FDA added a boxed warning for acute liver failure to Sarepta's ELEVIDYS and restricted use to ambulatory DMD patients. Key implications for AAV gene therapy QA and regulatory teams.
FDA approved NUVAXOVID for high-risk populations only. What the narrowed indication and iterative 2025 approval actions mean for biologics manufacturers and BLA strategy.
Oryzon's ALICE-2 trial reports 100% ORR with iadademstat triplet in AML. A 2027 registrational study raises CMC and LSD1 inhibitor manufacturing questions.
FDA grants Priority Review for Roche's Tecentriq sBLA in stage III dMMR colon cancer, with a 9 October 2026 PDUFA date covering IV and subcutaneous formulations.
Cellectis reports 100% ORR for allogeneic CAR-T lasme-cel in BALLI-01 Phase 1. Pivotal Phase 2 open; interim data expected Q4 2026. GMP scale-up implications.
Curium Group, PeptiDream, and PDRadiopharma complete patient dosing in Japan's Phase 2 trial for 64Cu-PSMA-I&T. Data analysis underway for regulatory submission.
Novartis FORTITUDE Phase I/II data confirm del-brax target engagement in FSHD. Phase III enrolling; regulatory discussions on Phase I/II dataset planned.
Medicus Pharma files IND for PRECISION-E2, a genomics-integrated Phase 2a trial of Teverelix in endometriosis using the Emirati Genome Program. Key implications for CMC and bioanalytical teams.
EMA's 2025 annual report records 104 human medicine recommendations, ESMP operationalisation, and the EMANS 2028 launch. Key implications for EU regulatory and GMP compliance planning.
Bayer's asundexian clears EMA validation and enters CHMP centralized review. Key implications for QA directors and plant heads on process validation and launch readiness.
Nurix Therapeutics reports 92.9% ORR for BTK degrader bexobrutideg in Phase 1a/b CLL trial at EHA 2026, with Phase 3 and Roche collaboration advancing.
Syndax publishes SAVE Phase 1/2 data in JCO: 88% ORR for all-oral revumenib triplet in R/R AML. Key implications for supplemental BLA and label expansion strategy.
Novo Nordisk confirms unauthorised IT access and data exfiltration. QA directors and plant heads face data integrity obligations under 21 CFR Part 11 and EU Annex 11.
MHRA approves Novo Nordisk's Wegovy pill (semaglutide 25 mg), the first oral GLP-1 weight-loss tablet in the UK. Private prescription launch expected within weeks.
Alembic Pharmaceuticals secures USFDA tentative approval for generic Larotrectinib capsules as sole first ANDA applicant, qualifying for 180-day exclusivity on Bayer's Vitrakvi.
AstraZeneca secures CDSCO approval for Trastuzumab Deruxtecan plus Pertuzumab in HER2-positive breast cancer. Key implications for ADC manufacturers and biosimilar developers in India.
Adial Pharmaceuticals acquires Azora Therapeutics, adding colon-targeted AhR agonist AT177 and up to $64M financing ahead of a mid-2027 Phase 1 UC study.
FDA authorizes generic Nitenpyram Tablets under EUA for New World screwworm treatment in dogs and cats. Key implications for generic drug manufacturers and QA leads.
60 Degrees Pharmaceuticals licenses FSU patent for castanospermine extraction while resolving FDA NDIN feedback ahead of a July 1, 2026 agency meeting.
KOMET-007 shows 94% 12-month OS in NPM1-m AML. As KOMET-017 Phase 3 advances, CMC scale-up and combination-use regulatory pathways move into focus.
Sygnature Discovery and DaltonTx integrate AI medicinal chemistry tools to cut synthesis cycles and accelerate candidate handoffs. Key read for CMOs and development leads.
Pfizer, Sandoz, and Astellas confirm voriconazole IV and AmBisome supply with drop-shipment protocols for hospitals during the fungal meningitis outbreak.
FDA CBER's 2024 patient listening meeting on gene therapy safety is shaping post-market registry and long-term follow-up obligations. Key read for biologics QA and regulatory teams.
Ascendis Pharma's five-year Phase 2 data for TransCon PTH show 82% response rates in hypoparathyroidism, raising GMP and process validation priorities for manufacturing teams.
ASSOCHAM projects India's pharma market at US$130B and exports at US$80B by 2030. Key implications for CDMO sourcing, biosimilar supply chains, and GMP compliance.
IPC's IP 2026 scientific conclave sets the stage for new GMP and quality standard obligations. Key implications for plant heads and QA directors in India.
KIHT receives government approval to conduct clinical research for drugs and medical devices, expanding India's CRO capacity under CDSCO oversight.
AbbVie's final CLL14 Phase 3 results show 7.6-year median TTNT for venetoclax in first-line CLL, with supply chain and lifecycle management implications.
Novartis submits sNDA for Rhapsido in symptomatic dermographism after Phase III RemIND data show doubled complete response rates vs placebo in CIndU.
EMA PRAC finds inconclusive NDD evidence for paternal valproate exposure, retains 2024 precautions, and mandates product information updates ahead of 2028 PASS study.
Medline's Class I correction for convenience kits containing Huons Bupivacaine HCl in Dextrose Injection follows an FDA manufacturing inspection. QA action required.
FDA CDER releases draft Q&A guidance on Forms 3542a and 3542 for promotional labeling submissions. Docket FDA-2026-D-2698 open for comment under 21 CFR 10.115.
Ipca Labs and BRL sign a co-development deal for next-gen biologics in oncology and autoimmune disease. Key implications for QA, regulatory, and manufacturing leads.
LIXTE Biotechnology exits pharma via acquisition of NOMAD Transportable Power Systems. Company to rename as NOMAD Power Solutions. No financial terms disclosed.
Roche's VENTANA PTEN (SP218) RxDx Assay gains FDA approval as the first IHC CDx for PTEN protein loss in prostate cancer, enabling capivasertib patient selection.
FDA approved Merck's belzutifan plus pembrolizumab for adjuvant clear cell RCC on June 12, 2026. Three-product labeling and subcutaneous formulation variants add manufacturing complexity.
FDA approves Tzield (teplizumab) for pediatric Stage 3 T1D ages 8–17. QA and regulatory teams face new IV biologic dosing, EBV/CMV screening, and sterility assurance requirements.
FDA grants Sanofi accelerated approval for Tzield in pediatric stage 3 type 1 diabetes. Confirmatory BETA-PRESERVE trial now enrolling. Key regulatory implications inside.
Novo Nordisk confirms a cyber breach involving personal data. QA and regulatory leads should assess 21 CFR Part 11 and ICH Q10 obligations in response.
Molbio Diagnostics' Truenat HPV-HR Plus becomes the world's first WHO-IARC validated reduced-valency HPV DNA test, with implications for Indian biotech global market access.
WHO SEARO and George Institute launch a two-year AI and real-world evidence collaboration for NCDs in South-East Asia, with implications for regional regulatory submissions.
MonumenTAL-3 Phase 3 data show talquetamab plus daratumumab cuts myeloma progression risk by 72%. Key implications for bispecific biologics manufacturers.
Ascendis Pharma's 182-week Phase 3 PaTHway Trial data show 86% response rate for palopegteriparatide, raising the manufacturing comparability bar for prodrug conjugate biologics.
Alembic Pharmaceuticals secures USFDA ANDA approval for Tretinoin Cream, therapeutically equivalent to Retin-A Cream, expanding its US dermatology generics portfolio.
Nara Organics recalls all powdered infant formula lots after three infant botulism cases. No positive product tests yet. QA and GMP implications examined.
Mineralys Therapeutics presents proteomic heart failure biomarker data for lorundrostat at ENDO 2026. FDA PDUFA date is December 22, 2026. CMC implications for QA leads.
The India-France Innovation Roadmap 2030 opens EU regulatory alignment pathways and CDMO partnership channels for Indian pharma manufacturers. Key implications inside.
Intravacc and SynphaBase form a strategic partnership linking synthetic oligosaccharide supply with GMP conjugate vaccine manufacturing for clinical developers.
XORTX advances XRx-026 toward a 505(b)(2) NDA after Type B FDA meeting, with CMC scale-up and bridging study XRX-OXY-102 running concurrently.
Cormica publishes orthogonal AIVC case study aligned with FDA Q3 guidance for topical ANDAs, covering MDRS, Raman, XRD, and rheology for formulation equivalence.
Reunion Neuroscience names Sahil V. Kirpekar President and CEO as luvesilocin Phase 2 trials expand into anxiety and adjustment disorder indications.
Elicio Therapeutics' AMPLIFY-7P missed its primary DFS endpoint but R0 subgroup data and mKRAS immune response findings shape a refined Phase 3 strategy.
IDEAYA Biosciences enrols first patient in IDE892 Phase 1/2 combination trial for MTAP-deleted cancers. CYP3A4 profile and CMC implications reviewed.
EMA's June 2026 Management Board advances new EU pharmaceutical legislation, records 30 veterinary approvals, and flags Biotech Act changes to clinical trial systems.
Medicus Pharma files an FDA Rare Pediatric Disease Designation request for SkinJect, layering it with Orphan Drug Designation and a registrational study under review.
ZoBio launches a DNA-encoded library platform to improve hit identification on difficult targets, expanding its fragment-based CRO discovery services.
Lonza signs ADC development deal with Antharis Therapeutics targeting GI cancers. Key implications for process validation, conjugation complexity, and CDMO strategy.
Medtronic introduces the PulseSelect Pulsed Field Ablation system in India. Key regulatory and QA implications for cardiac device teams under CDSCO Medical Devices Rules.
ACG deploys Golden Batch and Chanakya AI systems to improve first-pass yield and cut defect PPM in capsule and packaging materials manufacturing.
FDA's risk-based import screening ties GMP compliance under 21 CFR Parts 210 and 211 to shipment admissibility. Key implications for QA and supply chain leads.
FDA's final PLAIR guidance sets 60- and 120-day import windows for unapproved finished drugs. Submissions required via CDER NexGen Portal. Key read for regulatory teams.
FDA reaffirms import requirements for human drugs covering CGMP, establishment registration, drug listing, and labeling under FD&C Act and 21 CFR Parts 210–211.
Betterbrand promotes BetterLungs, an NAC-based dietary supplement, as wildfire smoke drives AQI past unhealthy thresholds across the U.S. in 2026.
SpyGlass Pharma names Shannon Treviño as General Counsel as BIM-IOL Phase 3 trials advance toward NDA submission. Key regulatory and manufacturing implications ahead.
FDA's July 2026 workshop examines efficacy extrapolation and evidence generation for pediatric antihypertensive therapies, with focus on children under six.
Confo Therapeutics advances CFTX-2034, an SSTR5 antibody for post-bariatric hypoglycemia, into IND-enabling studies following preclinical data at ENDO 2026.
Taro Pharmaceutical enters the Lamotrigine ODT generic market with AB-rated tablets in 25, 50, 100, and 200 mg, enabling formulary substitution for Lamictal ODT.
FDA's risk-based inspections target ophthalmic manufacturers following 2023–2024 contamination recalls. Key compliance implications for QA directors and plant heads.
FDA approves Tzield for pediatric Stage 3 type 1 diabetes via accelerated pathway using C-peptide surrogate endpoint. Boxed warning updated for viral reactivation.
India's bioeconomy reached $190 billion over 12 years. What indigenous CAR-T therapy and CDMO capacity growth mean for global pharma supply chains and GMP compliance.
Alithea Genomics and Revvity integrate MERCURIUS DRUG-seq into global screening portfolios, scaling transcriptomic profiling for early drug discovery pipelines.
FDA updated approval for Grifols' Procleix Babesia Assay on the Panther System. Key pooling rules and SOP implications for blood bank and biologics compliance leads.
Alithea Genomics and Revvity integrate MERCURIUS DRUG-seq into a global screening portfolio, expanding scalable transcriptomic profiling for AI-driven drug discovery.
Lilly's Jaypirca cuts CLL progression risk by 45% in Phase 3. What a label expansion means for BTK inhibitor manufacturing scale-up and process validation.
Roche gains FDA approval for the first PTEN-loss companion diagnostic in prostate cancer, setting a 21 CFR Part 809 precedent for CDx co-development and labeling.
FDA's June 2026 approval letter covers Grifols' Procleix WNV, Babesia, and Ultrio Elite assays. Key compliance details for blood center QA and regulatory leads.
FDA's June 2026 supplemental approval of Takeda's HYQVIA for CIDP maintenance therapy has GMP and labeling implications for biologics manufacturers. Full analysis.
Pasithea Therapeutics expands PAS-004 NF1 trial with new dose cohorts at 24 mg and 32 mg, 18-month treatment window, and enhanced imaging endpoints. Q4 2026 interim data on track.
Mabion partners with Oddifact to advance MabionCD20 into a rare disease indication, shifting from a biosimilar pathway to orphan drug development.
3PBIOVIAN's position paper argues proof-of-concept CDMO engagement reduces regulatory risk and compresses timelines in AAV gene therapy manufacturing programs.
Cognition Therapeutics receives USPTO Notice of Allowance for a polymorphic crystalline form patent on zervimesine (CT1812), extending exclusivity through 2045 or 2050.
Allergan Aesthetics gains FDA approval for SKINVIVE's neck-line indication, its second cleared use. Mandatory provider training required pre-purchase. Details inside.
FDA approves Amphastar's Rextovy 4mg OTC naloxone nasal spray on June 16, 2026. Key manufacturing, QA, and regulatory implications for pharma operations teams.
FibroBiologics doses first DFU patients in CYWC628 Phase 1/2 trial while completing a third consecutive GMP run, raising key ATMP reproducibility and batch release questions.
Koi Peptides releases a lyophilized BPC-157 and TB-500 research blend with per-lot Certificate of Analysis, HPLC purity, and mass spectrometry identity testing.
Horphag Research advances Pycnogenol® as a multi-claim women's health ingredient with 160+ clinical studies covering menopause, skin, circulation, and joints.
FDA issues June 15, 2026 approval letter for Vertex's CASGEVY under STN 125787. Key compliance and GMP implications for ATMP and CRISPR-based gene therapy manufacturers.
Rigel Pharmaceuticals closes $70M global license for VEPPANU (vepdegestrant) from Arvinas and Pfizer, targeting August 2026 commercial launch for ESR1-mutated breast cancer.
FDA sets MIC and disk diffusion breakpoints for tebipenem pivoxil, the first oral carbapenem. QC labs must qualify 10 mcg disk methods under 21 CFR Part 211.
FDA approves Utebzi (tebipenem pivoxil) as the first oral carbapenem for complicated UTIs. Key GMP, process validation, and regulatory implications for manufacturers.
Gelteq initiates human clinical trial in Q3 2026 and veterinary antiparasitic study targeting FDA application, while expanding oral peptide formulation pipeline.
Elicio Therapeutics reports three confirmed complete responses in metastatic pancreatic cancer after ELI-002 7P and nivolumab. Phase 1 combination study planned.
KPMG Global Tech Report 2026 finds life sciences firms scaling AI into GMP production environments, raising validation, QMS, and regulatory compliance questions.
Vygon secures Health Canada approval for its next-generation Stiletto Extended-Dwell Catheter. Key implications for QA, regulatory affairs, and sterile device manufacturers.